Higher temperatures linked to severity of allergic conjunctivitis

Article

Temperatures measured by a newly developed non-contact ocular surface thermographer (OST) can be used to evaluate the efficacy of topical anti-allergic agents because of the significant correlation of the conjunctival surface temperature and the severity of conjunctival allergic reaction, according to recently published data.

Temperatures measured by a newly developed non-contact ocular surface thermographer (OST) can be used to evaluate the efficacy of topical anti-allergic agents because of the significant correlation of the conjunctival surface temperature and the severity of conjunctival allergic reaction, according to the results of a study published in Ophthalmic Research.

Researchers from Ehime University School of Medicine included 13 asymptomatic patients with seasonal allergic conjunctivitis due to cedar pollen. They instilled a 0.025% levocabastine ophthalmic suspension in one eye and artificial tears in the other eye, in a masked fashion 10 minutes prior to a conjunctival allergen challenge (CAC). A drop of cedar pollen solution was then given into the conjunctival sac to induce an allergic reaction.

The surface temperature of the inferior bulbar conjunctiva was measured before and 30 minutes after CAC with a newly developed non-contact ocular surface thermographer (OST) Slit-lamp biomicroscopy was also used to measure the degree of conjunctival injection and chemosis. A questionnaire was used to evaluate symptoms.

After CAC, temperatures increased by 0.67 °C in the artificial tear eyes, and only by 0.21 °C in the levocabastine eyes (P P P

To access the abstract of this study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.